Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 270

1.

Is Personalized Medicine Here?

Carneiro BA, Costa R, Taxter T, Chandra S, Chae YK, Cristofanilli M, Giles FJ.

Oncology (Williston Park). 2016 Apr 15;30(4). pii: 216448. Review.

2.

Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkers.

Strauss WM, Carter C, Simmons J, Klem E, Goodman N, Vahidi B, Romero J, Masterman-Smith M, O'Regan R, Gogineni K, Schwartzberg L, Austin LK, Dempsey PW, Cristofanilli M.

Oncotarget. 2016 Mar 30. doi: 10.18632/oncotarget.8494. [Epub ahead of print]

3.

Inflammatory breast cancer: a new approach.

Cristofanilli M.

Lancet Oncol. 2016 Mar 28. pii: S1470-2045(16)00064-4. doi: 10.1016/S1470-2045(16)00064-4. [Epub ahead of print] No abstract available.

PMID:
27032300
4.

Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.

Harbeck N, Iyer S, Turner N, Cristofanilli M, Ro J, André F, Loi S, Verma S, Iwata H, Bhattacharyya H, Puyana Theall K, Bartlett CH, Loibl S.

Ann Oncol. 2016 Mar 30. pii: mdw139. [Epub ahead of print]

PMID:
27029704
5.

The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells.

Salem I, Alsalahi M, Chervoneva I, Aburto LD, Addya S, Ott GR, Ruggeri BA, Cristofanilli M, Fernandez SV.

Breast Cancer Res. 2016 Mar 24;18(1):37. doi: 10.1186/s13058-016-0694-4.

6.

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon D.

Lancet Oncol. 2016 Mar 2. pii: S1470-2045(15)00613-0. doi: 10.1016/S1470-2045(15)00613-0. [Epub ahead of print]

PMID:
26947331
7.

MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer.

Huo L, Wang Y, Gong Y, Krishnamurthy S, Wang J, Diao L, Liu CG, Liu X, Lin F, Symmans WF, Wei W, Zhang X, Sun L, Alvarez RH, Ueno NT, Fouad TM, Harano K, Debeb BG, Wu Y, Reuben J, Cristofanilli M, Zuo Z.

Mod Pathol. 2016 Apr;29(4):330-46. doi: 10.1038/modpathol.2016.38. Epub 2016 Feb 26.

PMID:
26916073
9.

CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer.

Mego M, Cholujova D, Minarik G, Sedlackova T, Gronesova P, Karaba M, Benca J, Cingelova S, Cierna Z, Manasova D, Pindak D, Sufliarsky J, Cristofanilli M, Reuben JM, Mardiak J.

BMC Cancer. 2016 Feb 19;16(1):127. doi: 10.1186/s12885-016-2143-2.

10.

Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells.

Terai M, Mu Z, Eschelman DJ, Gonsalves CF, Kageyama K, Chervoneva I, Orloff M, Weight R, Mastrangelo MJ, Cristofanilli M, Sato T.

EBioMedicine. 2015 Sep 18;2(11):1821-6. doi: 10.1016/j.ebiom.2015.09.019. eCollection 2015 Nov.

11.

Breast Cancer Stem Cell Isolation.

Jiao X, Rizvanov AA, Cristofanilli M, Miftakhova RR, Pestell RG.

Methods Mol Biol. 2016;1406:121-35. doi: 10.1007/978-1-4939-3444-7_10.

PMID:
26820950
12.

Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples.

Gogoi P, Sepehri S, Zhou Y, Gorin MA, Paolillo C, Capoluongo E, Gleason K, Payne A, Boniface B, Cristofanilli M, Morgan TM, Fortina P, Pienta KJ, Handique K, Wang Y.

PLoS One. 2016 Jan 25;11(1):e0147400. doi: 10.1371/journal.pone.0147400. eCollection 2016.

13.

Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.

Mu Z, Wang C, Ye Z, Austin L, Civan J, Hyslop T, Palazzo JP, Jaslow R, Li B, Myers RE, Jiang J, Xing J, Yang H, Cristofanilli M.

Breast Cancer Res Treat. 2015 Dec;154(3):563-71. doi: 10.1007/s10549-015-3636-4. Epub 2015 Nov 16.

PMID:
26573830
14.

A Preclinical Model of Inflammatory Breast Cancer to Study the Involvement of CXCR4 and ACKR3 in the Metastatic Process.

Wurth R, Tarn K, Jernigan D, Fernandez SV, Cristofanilli M, Fatatis A, Meucci O.

Transl Oncol. 2015 Oct;8(5):358-67. doi: 10.1016/j.tranon.2015.07.002.

15.

Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Turner NC, Huang Bartlett C, Cristofanilli M.

N Engl J Med. 2015 Oct 22;373(17):1672-3. doi: 10.1056/NEJMc1510345. No abstract available.

16.

Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.

Ross JS, Ali SM, Wang K, Khaira D, Palma NA, Chmielecki J, Palmer GA, Morosini D, Elvin JA, Fernandez SV, Miller VA, Stephens PJ, Cristofanilli M.

Breast Cancer Res Treat. 2015 Nov;154(1):155-62. doi: 10.1007/s10549-015-3592-z. Epub 2015 Oct 12.

PMID:
26458824
17.

Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups.

Yao K, Goldschmidt R, Turk M, Wesseling J, Stork-Sloots L, de Snoo F, Cristofanilli M.

Breast Cancer Res Treat. 2015 Nov;154(1):81-8. doi: 10.1007/s10549-015-3587-9. Epub 2015 Sep 30.

18.

The effects of erythropoiesis-stimulating agents on the short-term and long-term survivals in metastatic breast cancer patients receiving chemotherapy: a SEER population-based study.

Lai Y, Ye Z, Civan JM, Wang C, Cristofanilli M, Mu Z, Austin L, Palazzo JP, Myers RE, Yang H.

Breast Cancer Res Treat. 2015 Sep;153(2):407-16. doi: 10.1007/s10549-015-3532-y. Epub 2015 Aug 12.

PMID:
26264468
19.

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC Jr, Bennett JM, Benz EJ Jr, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ Jr, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA.

Mayo Clin Proc. 2015 Aug;90(8):996-1000. doi: 10.1016/j.mayocp.2015.06.001. Epub 2015 Jul 23. No abstract available.

PMID:
26211600
20.

Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells.

Cohen EN, Gao H, Anfossi S, Mego M, Reddy NG, Debeb B, Giordano A, Tin S, Wu Q, Garza RJ, Cristofanilli M, Mani SA, Croix DA, Ueno NT, Woodward WA, Luthra R, Krishnamurthy S, Reuben JM.

PLoS One. 2015 Jul 24;10(7):e0132710. doi: 10.1371/journal.pone.0132710. eCollection 2015.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk